The use of vaccines for prevention of seasonal and pandemic influenzaArchived
On 3 October 2011 European Centre for Disease Prevention and Control (ECDC) and representatives of the European Vaccine Manufacturers met at ECDC in Stockholm for a regular scheduled meeting about the use of vaccines for prevention of seasonal and pandemic influenza. ECDC Director Marc Sprenger opened the meeting and ECDC influenza experts held different presentations, such as burden of influenza disease in the EU, risk groups for severe influenza disease, personal protective measures, pandemic influenza preparedness, seasonal influenza vaccines, communication.
The Declarations of Interest for ECDC Influenza Staff and the ECDC Director are available here under ECDC Transparency.
On 3 October 2011 European Centre for Disease Prevention and Control (ECDC) and representatives of the European Vaccine Manufacturers met at ECDC in Stockholm for a regular scheduled meeting about the use of vaccines for prevention of seasonal and pandemic influenza. ECDC Director Marc Sprenger opened the meeting and ECDC influenza experts held different presentations, such as burden of influenza disease in the EU, risk groups for severe influenza disease, personal protective measures, pandemic influenza preparedness, seasonal influenza vaccines, communication.
Agenda : The use of vaccines for prevention of seasonal and pandemic influenza Moderator: Deputy Chief Scientist Piotr Kramarz
|
|
9.00 - 9.10 |
Welcome note by Director Marc Sprenger |
09.10-09.20 |
General Introduction |
9.20 – 10:00 |
9.20 - 9.30: Introduction to Ongoing and planned activities for 2012 (Angus Nicoll) 09.30 – 9.50 Seasonal influenza: General influenza surveillance
9.50 -10.00Coming systematic reviews (Bruno Ciancio, Vicente Lopez and Angus Nicoll):
|
10.00- 10.25 |
Pandemic influenza preparednessLessons learnt from the pandemic influenza A/H1N1 2009 and re-writing of pandemic plans (Pasi Penttinen and Angus Nicoll) |
10.25-10.40 |
PIP- pandemic influenza preparedness agreement (Atika Abelin) |
10.40 – 11.00 |
Coffee break |
11.00 – 12.30 |
Seasonal influenza vaccines 11.00- 11.20: Monitoring coverage and VENICE outputs in 2011 and 2012 – (PierLuigi Lopalco and Teymur Noori) Capacity to assess influenza vaccine coverage in the EU – where are the gaps.
11.20 – 11.35: Capacity to assess influenza vaccine effectiveness – presentation of the I-MOVE project including strengths and limitations and future (Bruno Ciancio)
11.35 – 11.50: Capacity to assess influenza vaccine safety – presentation of the VAESCO project including strengths and limitations and future (Kari Johansen)
11.50 – 12.00: Interactions with EMA specifically related to seasonal and pandemic influenza vaccines – risk management plans (Kari Johansen)
12.00- 12.10: A Health Economics Tool Kit for Flu Immunisation – is it needed (Angus Nicoll) Communication
12.10- 12.20: Scientific Advances and Public Health Developments (Angus Nicoll) 12.20-12.30: Overview of ECDC Influenza Workshops week 10-14 October, 2011 and later events (Angus Nicoll)
|
12.30 – 13.30 |
Lunch |
13.30 – 17.00 |
Individual presentations by the vaccine manufacturers |